Document is current
Any future updates will be listed below
-
Authors
Desert, Romain
Gianonne, Fabio
Saviano, Antonio
Hoshida, Yujin
Heikenwälder, Mathias
Nahon, Pierre
Baumert, Thomas F.
- License Information
-
More Information
Article History
Received: 25 October 2024
Accepted: 28 January 2025
First Online: 3 April 2025
Competing interests
: The authors declare no competing interests.
: Inserm, the University of Strasbourg, the Strasbourg University Hospitals and the IHU Strasbourg have filed patent applications for the use of anti-claudin-1 monoclonal antibodies for the treatment of fibrosis and cancers (T.F.B. inventor) which have been licensed to Alentis Therapeutics. The same organisations have also filed patent applications for a method for diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and discovery of therapeutic compounds and targets to treat liver disease and cancer as well as a clinical gene signature-based human cell culture model and uses thereof (T.F.B and Y.H. co-inventors). T.F.B. is founder, shareholder, and advisor for Alentis Therapeutics. P.N. has received honoraria from and/or consults for AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Gilead, Guerbet, Ipsen, and Roche. He has also received research grants from AstraZeneca, AbbVie, Bristol-Myers Squibb, and Eisai.
